Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Common Equity (2021 - 2025)

Historic Common Equity for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $147.7 million.

  • ARS Pharmaceuticals' Common Equity fell 2653.18% to $147.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.7 million, marking a year-over-year decrease of 2653.18%. This contributed to the annual value of $256.8 million for FY2024, which is 1128.36% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Common Equity stood at $147.7 million, which was down 2653.18% from $192.3 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Common Equity peaked at $368.5 million during Q1 2021, and registered a low of -$31.3 million during Q4 2021.
  • Its 5-year average for Common Equity is $240.8 million, with a median of $248.6 million in 2023.
  • In the last 5 years, ARS Pharmaceuticals' Common Equity surged by 97270.46% in 2022 and then crashed by 2653.18% in 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Common Equity (Quarter) stood at -$31.3 million in 2021, then skyrocketed by 972.7% to $272.9 million in 2022, then decreased by 15.44% to $230.8 million in 2023, then grew by 11.28% to $256.8 million in 2024, then plummeted by 42.5% to $147.7 million in 2025.
  • Its last three reported values are $147.7 million in Q3 2025, $192.3 million for Q2 2025, and $229.0 million during Q1 2025.